KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti-PD-1/L1 immunotherapy.
JOURNAL OF CLINICAL ONCOLOGY(2020)
摘要
10072Background: MCC is an aggressive neuroendocrine skin cancer with very poor prognosis. Immune checkpoint inhibition was recently shown to benefit some patients (pts). There are few effective tr...
更多查看译文
关键词
merkel cell carcinoma,tp53,anti–pd-1/l1 immunotherapy,first-in-class,wild-type
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要